FY2025 · ended Dec 31, 2025 · Revenue $7.25M, +1181.3% YoY · Filed Mar 18, 2026
Ovid Therapeutics Inc. (OVID) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.3 million and a net loss of $17.4 million. Free cash flow was -$38.3 million. As of Jun 30, 2026 it held $169.8 million in cash and investments and $12.7 million in total debt.
Revenue (TTM)
$1.58M
-76.2% vs year-ago TTM
Net income (TTM)
$-34.49M
+9.7% vs year-ago TTM
Operating cash flow (TTM)
$-54.77M
-36.7% vs year-ago TTM
Free cash flow
$-38.33M
+31.6% vs prior year
EPS
$-0.74
+3.9% vs prior year
Dividend per share
None
Shares outstanding
131.87M
+85.5% vs prior year
Net cash
$157.05M
as of Jun 30, 2026
Operating margin
-3686.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OVID (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1636651
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $122.8M |
| Diluted EPS | — | — | -$0.74 | -$0.77 | $1.76 |
| Operating cash flow | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M |
| Free cash flow | -$38.3M | -$56.0M | -$45.8M | -$56.5M | $118.4M |
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M |
| Stockholders' equity | $130.7M | $68.2M | $87.8M | $132.3M | $179.7M |
| Cash and investments | $90.4M | $74.0M | $123.5M | $134.6M | $189.4M |
| Total debt | $13.4M | $14.8M | $16.0M | $16.5M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K | Current report | Aug 13, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 8, 2026 | Jul 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 3, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 532 Ovid Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.